Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Prosonix

- PMLiVE

Merck starts pivotal trials of new antibiotic combination

Continues testing after positive phase II results for relebactam addition 

National Institute for Health and Care Excellence NICE logo

NICE backs five new drugs after discounts agreed

Includes Novartis’ previously rejected lung cancer and melanoma therapies Zykadia and Mekinist

- PMLiVE

Takeda starts trial of norovirus vaccine

If approved the drug is anticipated to surpass sales of GSK’s Rotarix vaccine

- PMLiVE

Circassia slumps as cat allergy vaccine fails late-stage trial

Has suspended several trials after an “unprecedented” placebo effect derailed leading drug candidate

- PMLiVE

Trial backs Keytruda use first-line in lung cancer

Suggests Merck & Co’s drug is more effective than chemotherapy for NSCLC patients

UK flag

UK biotech beats fundraising records in 2015, says BIA

Record-breaking amount accounts for a third of all EU biotech venture finance last year

- PMLiVE

FDA approves first cholera vaccine in US

PaxVax’s oral vaccine Vaxchora will be launched by September

- PMLiVE

A rare opportunity

Sobi’s Neil Dugdale on how the UK’s approach to rare diseases is changing

Roche Basel Switzerland

Roche gets EU okay for Avastin/Tarceva combination

Lung cancer therapy ‘significantly’ extends progression-free survival

- PMLiVE

GSK and J&J move closer to sirukumab filing for arthritis

On course for third quarter application in a bid to catch up with Sanofi’s sarilumab

Daiichi Sankyo logo

Daiichi pulls study of patritumab in lung cancer

HER3 inhibitor candidate showed no evidence of efficacy in trial analysis

ABPI London offices

ABPI says UK role as clinical trial hub threatened by Brexit

Warns UK patients could be denied access to medical innovations as a result

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links